The Continued Need for Transparent Evidence on the Cost Effectiveness of Drugs for Rare Diseases

Jesse Elliott (), George A. Wells and Doug Coyle
Additional contact information
Jesse Elliott: University of Ottawa
George A. Wells: University of Ottawa
Doug Coyle: University of Ottawa

PharmacoEconomics, 2021, vol. 39, issue 4, No 10, 479-480

Date: 2021
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40273-021-01007-8 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:39:y:2021:i:4:d:10.1007_s40273-021-01007-8

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-021-01007-8

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().